IP Library Granted Patent US 9,125,927
Granted Patent B2
US 9,125,927 · App. 14/040,402 · Granted Sep 8, 2015

Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,125,927
App. No.
14/040,402
Granted
Sep 8, 2015
Kind
B2
Abstract

Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.

Claims (12)

1. A pharmaceutical/dermatological topically applicable composition useful for the treatment of rosacea in the absence of irritation and intolerance, comprising anti-rosacea effective amounts of ivermectin and azelaic acid or salt thereof, and an acrylamide/sodium acryloyldimethyl taurate copolymer/isohexadecane/polysorbate 80 gelling agent, formulated into a topically applicable, physiologically acceptable medium therefor, wherein ivermectin and azelaic acid or salt thereof are the only active anti-rosacea agents in the composition, said composition being formulated as a gel or as an emulsion.

2. The pharmaceutical/dermatological composition as defined by claim 1 , said ivermectin comprising from 0.001% to 10% by weight thereof and said azelaic acid or salt thereof comprising from 0.01% to 40% by weight thereof.

3. The pharmaceutical/dermatological composition as defined by claim 1 , further comprising at least one additive selected from the group consisting of chelating agents, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants, dyes, mineral acids, organic acids, mineral bases, organic bases, fragrances, essential oils, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, calmatives, skin-protecting agents, pro-penetrating agents and mixtures thereof.

4. A method for the treatment of rosacea, comprising topically administering to an individual in need of such treatment, a pharmaceutical/dermatological topically applicable composition as defined by claim 1 .

5. The pharmaceutical/dermatological composition as defined by claim 1 , said ivermectin comprising from 0.01% to 5% by weight thereof and said azelaic acid or salt thereof comprising from 1% to 20% by weight thereof.

6. The pharmaceutical/dermatological composition as defined by claim 5 , wherein the emulsion is a cream.

7. The method as defined by claim 4 , said ivermectin comprising from 0.01% to 5% by weight of the composition and said azelaic acid or salt thereof comprising from 1% to 20% by weight of the composition.

8. The method as defined by claim 7 , wherein the emulsion is a cream.

9. A pharmaceutical/dermatological topically applicable composition useful for the treatment of rosacea in the absence of irritation and intolerance, consisting of anti-rosacea effective amounts of ivermectin and azelaic acid or salt thereof, and an acrylamide/sodium acryloyldimethyl taurate copolymer/isohexadecane/polysorbate 80 gelling agent, formulated into a topically applicable, physiologically acceptable medium therefor, said medium consisting of: (a) at least one member selected from the group consisting of water, alcohols, oils, fatty substances and waxes, and (b) at least one additive selected from the group consisting of chelating agents, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants, dyes, mineral acids, mineral bases, organic acids, organic bases, fragrances, essential oils, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, calmatives, skin-protecting agents, pro-penetrating agents, emulsifiers, co-emulsifiers, and mixtures thereof; said composition being formulated as a gel or as an emulsion.

10. The pharmaceutical composition as defined by claim 9 , said ivermectin being from 0.01% to 5% by weight thereof and said azelaic acid or salt thereof being from 1% to 20% by weight thereof.

11. The pharmaceutical/dermatological composition as defined by claim 10 , wherein the emulsion is a cream.

12. A method for the treatment of rosacea, comprising topically administering to an individual in need of such treatment, an anti-rosacea effective amount of a composition as defined by claim 9 .

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
ASSET TRANSFER AGREEMENT Recorded Oct 3, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057698/0295 →
CHANGE OF NAME Recorded Oct 3, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057698/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2015
From: KAOUKHOV, ALEXANDRE; PERNIN, COLETTE
To: GALDERMA S.A.
Reel/Frame 035789/0106 →